Antiplatelet Therapy in Patients Receiving Percutaneous Coronary Intervention for Bifurcation Lesions
Korean Circulation Journal · 2026 · 56 (9) · 753
DOI: 10.4070/kcj.2025.0427 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Korean Circulation Journal, 2026. Verfasst von Jeehoon Kang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Seoul National University Hospital, Seoul, Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Antiplatelet therapy is crucial for patients after percutaneous coronary intervention (PCI), but there is limited high-quality evidence guiding the best strategy for those with bifurcation lesions. The antiplatelet strategy for bifurcation PCI requires balancing the patient's overall thrombotic and bleeding risks. Bifurcation lesions present a complex, high-thrombotic-risk milieu because the procedure often causes plaque disruption and forms an inevitable gap in the sealing of the stent, compounded by turbulent blood flow that promotes thrombosis. Factors like stent malapposition, underexpansion, and low/oscillatory shear stress also contribute to increased local thrombotic risk, making the optimal antiplatelet therapy for bifurcation PCI difficult to define. Previous observational registry data broadly suggested a prolonged duration of dual antiplatelet therapy (DAPT) may be safer than a shorter duration of DAPT in reducing major adverse clinical outcomes. However, the reliability of these findings is limited by the inherent flaws of registry data, including the retrospective study design, lack of clinical event adjudication, and lack of specific protocol of PCI or DAPT strategy. Moreover, specific lesions factors such as complex PCI and left main bifurcation lesions or patient factors such as the presence of high bleeding risk or clopidogrel resistance necessitate special consideration, which leads to a individualized DAPT strategy beyond registry generalizations. The future of care points toward precision medicine, necessitating dedicated, prospective randomized controlled trials with standardized procedures to establish clear, evidence-based recommendations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Seoul National University Hospital, Seoul, Korea.
- Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
- Division of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. bkkoo@snu.ac.kr.
ORCID-Profile: Jeehoon Kang, Bon-Kwon Koo
Zitieren
APA
Kang, J., & Koo, B. K. (2026). Antiplatelet Therapy in Patients Receiving Percutaneous Coronary Intervention for Bifurcation Lesions. Korean Circulation Journal, 56(9), 753. https://doi.org/10.4070/kcj.2025.0427
Vancouver
Kang J, Koo BK. Antiplatelet Therapy in Patients Receiving Percutaneous Coronary Intervention for Bifurcation Lesions. Korean Circulation Journal. 2026;56(9):753. doi:10.4070/kcj.2025.0427
BibTeX
@article{Kang2026,
author = {Kang, Jeehoon and Koo, Bon-Kwon},
title = {Antiplatelet Therapy in Patients Receiving Percutaneous Coronary Intervention for Bifurcation Lesions},
journal = {Korean Circulation Journal},
year = {2026},
volume = {56},
number = {9},
pages = {753},
doi = {10.4070/kcj.2025.0427}
}
EUVIMED